Alto Neuroscience Inc
Research Alto Neuroscience Inc (ANRO) on Bullrun: market cap USD 855.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANRO
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 855.24M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 27.64M
- Free cash flow-USD 19.76M
Valuation Snapshot
latest market cap is USD 855.24M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 63.24M | -USD 51.79M | n/a | -2.19 | USD 176.48M | USD 16.76M | USD 151.14M |
| FY2024 | USD 0 | -USD 61.43M | -USD 49.50M | n/a | -2.5 | USD 168.23M | USD 10.25M | USD 151.46M |
| FY2023 | USD 0 | -USD 36.31M | -USD 33.92M | n/a | -9.73 | USD 82.55M | USD 9.86M | -USD 71.67M |
| FY2022 | USD 0 | -USD 27.71M | -USD 21.13M | n/a | -2.13 | USD 48.34M | USD 9.75M | -USD 38.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 855.24M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 568.24M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 114.15M | n/a | n/a | n/a |
About Alto Neuroscience Inc
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alto Neuroscience Inc's market cap?
Alto Neuroscience Inc's market capitalization is USD 855.24M.
What does Alto Neuroscience Inc do?
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).